Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Bearish
7
Neutral
2
Bullish
5
Bearish
9
Neutral
2
Bullish
35
Bearish
2
Neutral
0
Bullish
30
Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India, offering services through hospitals, diagnostics, and day care specialty facilities.
In Q2 FY26, Fortis reported a revenue increase of 17.3% year-over-year to INR 2,331 Cr, with operating EBITDA margins improving from 21.9% to 23.9%.
Significant acquisitions and capacity expansions include a 31.5% stake in Agilus Diagnostics and new beds at Greater Noida and Jalandhar, broadening its healthcare facilities network.
The company has improved its hospital business's operational efficiency, with specialty areas like Oncology and Renal Sciences seeing over 20% growth in revenues.
Digital growth is also a focus, with 20.4% of hospital revenues now emerging from digital channels, enhancing accessibility and patient engagement.
Healthcare
Hospitals / Medical Services
69,222 Cr
Low Risk
68.7
59.9
2.9
7.3
1,105.00
521.05
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
7514.15 | 1,08,388 Cr | 59.48 | 11.93 | 0.17 | 18.39 | 16.07 | 8.50 | |
1053.65 | 1,02,530 Cr | 70.29 | 10.20 | 0.14 | 13.50 | 12.81 | 8.72 | |
916.90 | 69,222 Cr | 68.73 | 7.34 | 0.11 | 10.75 | 12.26 | 6.53 | |
1826.60 | 37,212 Cr | 43.90 | 9.17 | 0.25 | 20.82 | 17.75 | 10.07 | |
601.00 | 31,082 Cr | 85.73 | 7.43 | 0.80 | 8.18 | 10.11 | 4.60 | |
1136.55 | 30,467 Cr | 53.94 | 8.22 | 0.00 | 15.15 | 16.83 | 9.50 | |
683.60 | 27,354 Cr | 93.39 | 12.05 | 0.00 | 14.80 | 10.88 | 4.75 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Fortis Healthcare Ltd (FORTIS) is currently trading at 916.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India, offering services through hospitals, diagnostics, and day care specialty facilities. In Q2 FY26, Fortis reported a revenue increase of 17.3% year-over-year to INR 2,331 Cr, with operating EBITDA margins improving from 21.9% to 23.9%. Significant acquisitions and capacity expansions include a 31.5% stake in Agilus Diagnostics and new beds at Greater Noida and Jalandhar, broadening its healthcare facilities network. The company has improved its hospital business's operational efficiency, with specialty areas like Oncology and Renal Sciences seeing over 20% growth in revenues. Digital growth is also a focus, with 20.4% of hospital revenues now emerging from digital channels, enhancing accessibility and patient engagement.
Over the past 52 weeks, Fortis Healthcare Ltd has traded between a low of ₹521.05 and a high of ₹1,105.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Fortis Healthcare Ltd has a market capitalization of approximately 69,222.11. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Fortis Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 68.73 and operates in the Healthcare sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 69,222.11 Cr, Fortis Healthcare Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Fortis Healthcare Ltd operates in the Healthcare sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Fortis Healthcare Ltd is 68.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The key announcement was the proposal to establish five regional medical value tourism hubs in India through a public-private partnership model, which is expected to directly benefit hospital chains like Fortis.
Citi has initiated coverage on Fortis Healthcare with a 'Buy' rating and a price target of ₹1,120 per share, implying a potential upside of nearly 33% from its price on January 22, 2026.
The total acquisition cost is ₹430 crore. This amount includes the hospital's operations, the building, underlying land, an adjacent land parcel, and existing debt.
Newspaper Publication
Fortis Healthcare informed exchanges that newspaper publications containing its unaudited financial results for the quarter/period ended Dec 31, 2025 were published on Feb 14, 2026 (Financial Express and Rozana Spokesman) under Reg 30/47.
Board Meeting Outcome
Fortis Healthcare board (13‑Feb‑2026) approved unaudited standalone & consolidated results for quarter/period ended 31‑Dec‑2025, approved formulation of ESOP 2026 (pool of 1,50,99,163 options subject to shareholder/regulatory approvals) and revised the Related Party Transaction Policy.
Board Meeting Outcome
Board approved unaudited standalone & consolidated financial results for quarter/period ended Dec 31, 2025; approved ESOP 2026 (pool of 15,099,163 options convertible to equal number of shares, subject to shareholder and regulatory approvals); and adopted a revised Related Party Transaction Policy (updated policy attached).
Earnings Presentation
Fortis reported Q3 FY26 consolidated revenue of INR 2,265 Cr (+17.5% YoY), operating EBITDA INR 505 Cr (+34.8%, 22.3% margin), PBT before exceptional INR 312 Cr (+21.9%); PAT lower due to INR 55.2 Cr exceptional loss; net debt INR 2,547 Cr.
Earnings Presentation
Fortis reported Q3 FY26 consolidated revenue of INR 2,265 Cr (+17.5% YoY), operating EBITDA INR 505 Cr (+34.8%, margin 22.3%), PBT before exceptional INR 312 Cr (+21.9%), PAT INR 197 Cr (-22.4%) after ~INR 46 Cr exceptional loss; net debt INR 2,547 Cr; announced acquisitions including People Tree Hospital (Bengaluru) and stake in Agilus.
Financial Results
Fortis reports Q3 FY26 consolidated revenue INR 2,265 Cr (+17.5% YoY), operating EBITDA INR 505 Cr (+34.8%; margin 22.3%), PBT before exceptional INR 312 Cr (+21.9%); net debt INR 2,547 Cr; Bengaluru acquisition highlighted.
